Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
New Clinical Data from Phase 2 Trial of LUT014 for the Treatment of Patients With EGFRI-Induced Acneiform Rash Accepted for Oral Presentation at the Clinical Trials Plenary Session
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the upcoming presentation of the results of its double-blind, placebo-controlled phase 2 randomized clinical trial of lead compound, LUT014 gel. The topically-applied novel B-Raf inhibitor is optimized for paradoxical MAPK activation, for patients treated with epidermal growth factor receptor (EGFR) inhibitor therapy who develop dose-limiting acneiform rash. The new clinical data will be released in an oral presentation at the Clinical Trials Plenary Session at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, IL.
Presentation Details:
Presentation Title: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies
Presenting Author: Anisha B. Patel, MD, Associate Professor, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX
Abstract Number: CT018
Session Title: New Frontiers in Precision Oncology
Session Date: Sunday, April 27, 2025
Session Time: 3:30 pm – 5:30 pm CT
About EGFR Inhibitor-Induced RashEGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal, lung, head and neck, urinary bladder, pancreatic and breast cancers, eliciting downstream phosphorylation and activation of the MAP Kinase pathway.
EGFR inhibitors can block the EGFR signal responsible for cell growth. Among the various types of pharmacological therapies for cancer, EGFR inhibitors are increasingly being used both as primary therapy as well as in patients who have progressed on prior chemotherapy treatments. Although effective as anti-cancer therapy leading to tumor shrinkage, EGFR inhibitors have many adverse reactions associated with their use. The majority of patients treated with EGFR inhibitors will experience adverse dermatological side effects typically manifested as a papulopustular skin rash, also known as acneiform lesions, which can impact quality of life and affect adherence to therapy.
About LUT014LUT014 is a novel B-Raf inhibitor which is applied topically to the skin. When the B-Raf protein is mutated, as is the case in some human cancers such as melanoma, blocking this pathway leads to apoptosis of the cells and tumor shrinkage. However, when the same pathway is blocked in normal, non-mutated cells, the opposite happens: the MAPK pathway is activated, and cells start growing. This phenomenon is recognized as the paradoxical effect of B-Raf Inhibitors. LUT014 harnesses the paradoxical effect of B-Raf Inhibitors in order to enhance cell proliferation and balance cell destruction, typical to radiation dermatitis.
About Lutris PharmaLutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma's lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and has successfully completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients.
For more information, please visit www.lutris-pharma.com.
Contacts:
Lutris PharmaNoa Shelach, Ph.D. Chief Executive Officerir@lutris-pharma.com
Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lutris-pharma-to-present-at-the-american-association-for-cancer-research-annual-meeting-2025-302411050.html
SOURCE Lutris Pharma
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Heungkong, Panasonic and Tantron Unveil Breakthrough in Forest-Ecology-Inspired Indoor Bionic Technology
GUANGZHOU, China, June 10, 2025 /PRNewswire/ -- Heungkong Group, Panasonic Electric, and Tantron Technology have announced the mid-stage outcomes of their collaborative innovation, the "8 Constants+ Forest Environment System," on World Environment Day, June 5, 2025. This pioneering solution signifies a significant advancement at the intersection of smart environmental control, ecological science, and human well-being, setting a new benchmark for sustainable development. As the world's first intelligent indoor regulation system modeled on forest ecosystem dynamics, the 8 Constants + Forest Environment System applies the principles of environmental bionics to recreate a forest-like indoor environment. The system operates through eight core elements: constant temperature, humidity, oxygen level, cleanliness, quietness, airflow, intelligence, and control. Former Japanese Prime Minister Yukio Hatoyama and former European Council President and ex-Prime Minister of Sweden, John Fredrik Reinfeldt, delivered congratulatory video messages for the occasion. Mr. Hatoyama said, "Environmental challenges have become a critical global issue and we are making every effort to address it. This collaboration harnesses the technical strengths of China and Japan to create a new-generation atmospheric platform—a powerful example of bilateral innovation. We are confident that this advancement will support smarter, healthier, and more comfortable living environments for people in the two countries and beyond." Mr. Reinfeldt commended the milestone, stating that healthy indoor environments are a global priority and that the system sets an exemplary standard for indoor environmental enhancement worldwide. Experts in green technology, environmental systems, and health-focused architecture also commended the platform for its technical achievements. All-China Environment Federation chairman Wang Xiufeng commented, "The 8 Constants + Forest Environment System provides an intelligent ecological solution to address human health challenges. It demonstrates how advanced technologies can drive the shift toward sustainable living, while reinforcing the role of enterprises in promoting ecological stewardship and global climate action." Xing Lei, Secretary-General of the World Green Design Organization, added that the system delivers a novel model for sustainable and healthy living spaces. Heungkong Group chairwoman Mei Hing Chak said, "Technological innovation is the engine of our business strategy. By working closely with world-class scientific institutions and industrial partners, Heungkong has merged Panasonic's global leadership in environmental sensing, Tantron's proprietary algorithmic intelligence, and the practical ecosystem of our Heungkong-1 flagship residential project. The result is a new standard for indoor environmental science. In the years ahead, we will expand our innovation framework and deepen international partnerships to accelerate deployment and scalable impact." Matsui Jun, Head of Panasonic China & Northeast Asia's HVAC Division, described the joint project as a testament to China-Japan technical synergy, "This system will set new industry benchmarks for healthy living environments, delivering tangible benefits to communities and consumers." Tantron founder Yao Minghai noted, "The 8 Constants + Forest Environment System delivers multiple world-first innovations, most notably its self-learning natural language interface. Unlike conventional systems requiring precise commands, the system, for instance, interprets casual expressions like 'I'm sleepy' to automatically dim lights, adjust ambiance and optimize sleep temperature. This isn't just automation - it's an adaptive living system that anticipates needs and personalizes experiences." The '8 Constants+ Forest Environment System' brings together the core strengths of all three partners in a strategic collaboration: Panasonic provides the hardware platform, integrating its industry-leading precision sensors and HVAC technologies; Tantron drives innovation through proprietary AI algorithms and adaptive interaction architecture; and Heungkong Group leads scenario-based application and market enablement, drawing on its real-world project expertise to ensure scalable, ready-for-deployment solutions. View original content to download multimedia: SOURCE Heungkong Group
Yahoo
6 hours ago
- Yahoo
New data from DR.CI:LABO™ at IMCAS Asia 2025 reinforces leadership in adjunctive clinical skincare for daily and post-IPL care for Asian skin
SINGAPORE, June 10, 2025 /PRNewswire/ -- Japan's clinic-born leading derma-cosmetics brand, unveiled new findings at IMCAS Asia 2025, reaffirming its position as the go-to skincare brand for Asian skin. The data demonstrated the efficacy of VC100 Essence Lotion EX and 377VC Radiance Serum in improving skin hydration, elasticity, and pigmentation when used daily and post-IPL[1] care. "At IMCAS Asia 2025, we're proud to present new clinical evidence that reflects the needs of today's consumers and supports their aesthetic and skincare choices. Our role is to provide safe, effective skincare solutions like VC100 Essence Lotion EX and 377VC Radiance Serum that can be used as daily skincare, enhance recovery and extend results of aesthetic treatments," said Dr. Sheila Chua, Board-Certified Dermatologist and Head of Medical & Safety Sciences, Skin Health & Beauty, Kenvue Asia Pacific. VC100 Essence Lotion EX: Now with clinically proven efficacy for regular daily and post-IPL care At IMCAS Asia 2025, presented new clinical data highlighting the benefits of twice-daily use of VC100 Essence Lotion EX over eight weeks on Asian skin. Powered by 100 trillion Micro-High Penetrating APPS Vitamin C, the formulation delivered visible improvements across key skin indicators including hydration, elasticity and gloss by 21.6%, 14.6%, 8.7% respectively, and reduction in hyperpigmentation by 5.9%.[2] The study also showed a significant boost in the synthesis of five different types of collagen, increased collagen density, and skin firmness. This builds on findings presented at the American Academy of Dermatology 2025, where twice daily use of VC100 Essence Lotion EX and Emulsion over a span of eight weeks showed a similar trend of improvement to IPL.[3],[4] When used in combination with IPL, hydration and elasticity improved by 25.4% and 15.5% respectively, compared to 20.8% and 10.9% with IPL alone, and hyperpigmentation reduction accelerated, with visible improvement by Week Two. 377VC Radiance Serum: A proven brightening adjunct for IPL-treated skin also shared clinical data on 377VC Radiance Serum at IMCAS. In a five-week, randomized controlled trial, participants who used the serum daily post-IPL showed a 31.88% reduction in Melasma Area and Severity Index and a 22.13% reduction in hyperpigmentation, compared to 8.92% and 8.52% in participants that only received IPL.[5] Skin image analysis further indicates reversing and reduced risk of potential re-darkening after IPL. The serum was well tolerated on treated skin in favorable state, supporting its use in post-IPL care and reaffirming its safety profile.[5] Findings presented at IMCAS from a survey of 844 dermatologists in China validated clinical approach and reinforces its clinical credibility: 83% agreed that 377VC Radiance Serum reduces melanin synthesis and improves skin brightness, Over 75% believed it enhances post-IPL outcomes and helps prevent post-inflammatory hyperpigmentation, and 99% acknowledged growing patient demand for adjunctive clinical skincare.[6] For a detailed overview of products and posters exhibited, refer to the Data and Product Fact Sheet. For more information, visit the website. About Since 1999, has pioneered the advancement of skincare solutions in collagen health. For over 25 years, is dedicated to providing skincare solutions that unlock the potential for beauty within every skin and democratize access to clinic level treatments for all. [1] Intense Pulsed Laser [2] Taichi Nishizawa et. al., "Ex-vivo and Clinical Study of an Amphiphilic Vitamin C Derivative to Enhance Dermal Collagen and Skin Gloss", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [3] Frequency of IPL treatment administered: 3 times every 2 weeks, over 8 weeks (IPL output: 10-13J, about 100 shots). [4] Masahiko Ando et. al., Clinical efficacy assessment of skin care formulations containing trisodium ascorbyl6-palmitate 2-phosphate (APPS) for pre-aging skin, Poster number 61671, American Academy of Dermatology Annual Meeting, 7-11 March 2025, Orlando, Florida [5] Yueying Fu et. al., "Clinical Safety and Efficacy of a Novel Topical Phenylethyl Resorcinol Formulation for Intense Pulsed Light Adjunctive Usage for Solar Lentigo and Melasma skin", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand [6] Joleen Goh et. al., "Knowledge, Attitude, and Practice Towards the Adjunctive Perioperative Use of Phenylethyl Resorcinol with Aesthetic Treatments", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand View original content to download multimedia: SOURCE Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
APhA withholds endorsement of ACIP Adult Immunization Schedule
WASHINGTON, June 9, 2025 /PRNewswire/ -- APhA is the only pharmacy representative among several professional organizations that reviews and evaluates the ACIP Adult Immunization Schedule annually. Recently, there have been several updates to the COVID-19 vaccine recommendations made by the Department of Health & Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). These changes include removing the recommendation for people who are pregnant to receive the COVID-19 vaccine. Studies have shown that people who are pregnant or were recently pregnant are: More likely to get very sick from COVID-19 compared to those who are not. More likely to need hospitalization, intensive care, or the use of a ventilator or special equipment to breathe if they do get sick from COVID-19. At increased risk of complications that can affect pregnancy and the baby, including preterm birth or stillbirth. COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men. APhA's stance is that pregnancy is a high-risk condition; therefore, people who are pregnant should be recommended to receive the COVID-19 vaccine. The May 2025 updates to the COVID-19 vaccine recommendations do not appear to be based on the scientific evidence provided over the past few years. Considering this recent change, APhA has decided to withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025. This decision was proposed by a group of APhA members who are immunization subject matter experts and approved by the APhA Board of Trustees. APhA requests, and is hopeful, that future updates of the Adult Immunization Schedule be based on scientific evidence and would reconsider its endorsement upon the schedule being discussed and recommended by ACIP. View original content to download multimedia: SOURCE American Pharmacists Association